ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

General Practice

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

7,301Medicare Part D Prescriptions Filled, Including Refills

Rank: 27 out of 131

$491K Total Retail Price of All Prescriptions

Rank: 31 out of 131

317 Patients Receiving at Least One Drug in Part D
74%Patients 65 Years and Older
98% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in New York
Lower avg

Schedule Two
Controlled Substances

21% of this provider’s 317 patients filled at least one prescription for a schedule two drug, compared to an average of 6%.

Schedule Three
Controlled Substances

4% of this provider’s 317 patients filled at least one prescription for a schedule three drug, compared to an average of 8%.

Risky Drugs to Seniors

1% of this provider’s 5,808 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

36% of this provider’s prescriptions were for brand-name drugs, compared to an average of 29%.

Prescription Price

$67 was the average price of a prescription from this provider, compared to $68 among peers.

Prescriptions per Patient

23 is the average number of prescriptions (including refills) per patient, compared to an average of 22.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in New York
OMEPRAZOLE 298 230 1 4
NAPROXEN 204 165 2 69
ZOLPIDEM TARTRATE 192 163 3 15
OXYCODONE HCL 180 64 S2 4 107
TRAMADOL HCL 169 151 5 31
SIMVASTATIN 161 157 6 1
AMLODIPINE BESYLATE 157 118 7 2
IBUPROFEN 148 110 8 48
ENALAPRIL MALEATE 134 115 9 18
INDAPAMIDE 122 103 10 196
JANUVIA 118 96 11 32
METFORMIN HCL 111 111 12 8
NEXIUM 111 93 12 16
VENTOLIN HFA 110 70 14 85
DIOVAN 105 76 15 30
AMITIZA 102 87 16 159
VOLTAREN 93 78 17 59
EXFORGE 92 87 18 144
CILOSTAZOL 89 80 19 260
LISINOPRIL 88 68 20 6
PROAIR HFA 84 52 21 65
DESOXIMETASONE 83 75 22 156
ALENDRONATE SODIUM 81 77 23 23
AZITHROMYCIN 81 68 23 38
MECLIZINE HCL 81 69 23 79
DIOVAN HCT 80 78 26 62
SINGULAIR 80 63 26 56
AMMONIUM LACTATE 77 68 28 76
AMLODIPINE BESYLATE-BENAZEPRIL 76 76 29 66
GLIMEPIRIDE 74 74 30 81
DICLOFENAC SODIUM 71 63 31 142
TAMSULOSIN HCL 69 69 32 24
GLYBURIDE-METFORMIN HCL 68 48 R 33 80
METOPROLOL TARTRATE 67 66 34 7
PLAVIX 67 66 34 36
PATADAY 60 46 36 170
CHLORHEXIDINE GLUCONATE 59 55 37 137
CLOPIDOGREL 58 57 38 28
ATENOLOL 56 48 39 14
CICLOPIROX 55 40 40 183
LOVAZA 55 45 40 41
HYDROCORTISONE 53 32 42 199
ADVAIR DISKUS 51 28 43 33
METOPROLOL SUCCINATE 51 46 43 10
LOSARTAN-HYDROCHLOROTHIAZIDE 51 40 43 58
ONGLYZA 50 50 46 217
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 8, 2007.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.